{"schema_version":"secwatch.filing_event.v1","accession":"0001600620-23-000028","form_type":"8-K","ticker":"AUPH","cik":"0001600620","company_name":"Aurinia Pharmaceuticals Inc.","filed_at":"2023-08-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:34.502432+00:00","generated_at":"2026-06-12T08:22:20.169809+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Aurinia Q2 revenue up 47% to $41.5M; raises FY 2023 guidance to $150-160M","bullets":["Q2 net revenue $41.5M (+47% YoY); net loss narrowed to $11.5M ($0.08 loss per share) from $35.5M ($0.25).","Raised FY2023 LUPKYNIS revenue guidance to $150-160M; cited strong commercial execution.","Patients on therapy reached 1,911 (+50% YoY); patient start forms +10% YoY to 451 in Q2.","Gross margin 96%; cash and short-term investments $350.7M as of June 30, 2023.","Initiated strategic review with J.P. Morgan as financial advisor."],"urls":{"canonical":"https://secwatch.observer/filing/0001600620-23-000028","json":"https://secwatch.observer/filing/0001600620-23-000028.json","markdown":"https://secwatch.observer/filing/0001600620-23-000028.md","text":"https://secwatch.observer/filing/0001600620-23-000028.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1600620/000160062023000028/0001600620-23-000028-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1600620/000160062023000028/auph-20230803.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-12T08:22:20.169809+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"ef82a71df6a691410051f1b7d6eba71d0f9e17a8","claim":"Aurinia Pharmaceuticals Inc. reported three and six months ended June 30, 2023 results: revenue $41.5 million. Guidance raised.","evidence_excerpt":"Total net revenue was $41.5 million for the three months ended June 30, 2023","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1600620/000160062023000028/0001600620-23-000028-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"three and six months ended June 30, 2023"},{"label":"Revenue","value":"$41.5 million"},{"label":"Guidance","value":"raised"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}